GENB
Strong SellSinkerGenerate Biomedicines, Inc. · Healthcare · United States · $1.6B cap · $13.0M/day traded
$12.35 -0.5% · close 26 Oct · scored 27 Oct
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
As of 27 Oct 2026, MoatMap's StockRank for Generate Biomedicines, Inc. (GENB) is 8/100, ranked against 24,000+ stocks in 35 markets (Quality 19, Value 25, Momentum 34, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT GENERATE BIOMEDICINES, INC.
Read
Generate Biomedicines, Inc. is a biotechnology company pioneering a machine learning-powered generative biology platform to create novel protein therapeutics. It leverages AI and computational biology to design and optimize drugs from scratch, accelerating discovery and expanding the druggable target space. This is a cutting-edge biotech firm at the forefront of AI-driven drug discovery, aiming to revolutionize therapeutic development.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | 20.5M | 31.9M | 26.5M | 29.7M | 23.8M | -13.6% |
| EPS | -2.09 | -2.18 | -2.44 | -2.30 | -2.28 | — |
| Shares | 127.5M | 127.5M | 128.4M | — | — | — |
| Debt | 77.0M | 68.5M | 62.6M | — | — | — |
| Equity | -434.5M | -616.0M | — | — | — | — |
| Op CF | -117.8M | -200.6M | -237.0M | — | — | — |
| Inv CF | -57.7M | 116.8M | — | — | — | — |
| Fin CF | 91.3M | 28.1M | — | — | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GENB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc.(you) | $1.6B | 8 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $1.6B | 9 | Strong Sell |
| LYCA | Lycia Therapeutics, Inc. | $1.6B | 10 | Strong Sell |
| OCUL | Ocular Therapeutix, Inc. | $1.4B | 7 | Strong Sell |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.5B | 11 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.6B | 11 | Strong Sell |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.9B | 7 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.3B | 8 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.4B | 5 | Strong Sell |
| VERA | Vera Therapeutics, Inc. | $2.0B | 10 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.